Education
School ¡X Major ¡X Degree | Duration |
---|---|
°ª¶¯Âå¾Ç¤j¾Ç ¡X Âå¾Ç¬ã¨s©Ò(²¦) ¡X ³Õ¤h Doctorate, Graduate Institute of Medicine, Kaohsiung Medical University |
2008/08 ¡X 2016/06 |
°ª¶¯Âå¾Ç¤j¾Ç ¡X Âå¾Ç¬ã¨s©Ò(²¦) ¡X ºÓ¤h Master, Graduate Institute of Medicine, Kaohsiung Medical University |
¡X 2005/06 |
°ª¶¯Âå¾Ç°| ¡X Âå¾Ç¨t(²¦) ¡X ¾Ç¤h Bachelor, School of Medicine, Kaohsiung Medical College |
¡X 1999/06 |
Intramural Experience
Office/Department/Institute | Position | Duration |
---|---|---|
¤º¬ì³¡ | Visiting Staff | ¡X |
¤º¬ì¾Ç¬ì Department of Internal Medicine | Professor | 2023/02/01 ¡X |
¤º¬ì¾Ç¬ì Department of Internal Medicine | Associate Professor | 2019/08/01 ¡X 2023/01/31 |
¤º¬ì¾Ç¬ì Department of Internal Medicine | Assistant Professor | 2014/02/01 ¡X 2019/07/31 |
Extramural Experience
Discipline
Research & Technology Platform Open to the Outside
Interested Area(s)for Interdisciplinary Research
©Ò¦³¬ÛÃö»â°ì
all related topics with potential and impact.
Area(s) of Expertise & Research
Á{§É¤è±: ¦¨¤H¤ßŦ¬ì¯e¯f¥]¬A«aª¬°Ê¯ß¯e¯f¡B¤ß«ß¤£¾ã¡B佤¤ßŦ¯f¡B¤ß°IºÜ¡B¤ß¦Ù¯fÅܵ¥¶EÂ_¡BªvÀø»P¹w¨¾¡B¤ßŦ«æ«¯gÂåÀø¡B¤ßŦ¶Wµªi¾Þ§@»P¶EÂ_¡C ¬ã¨s¤è±: ¯×½èP¯f¾÷Âà¬ã¨s¡B¤ßŦ¹q¥Í²z¬ÛÃö¬ã¨s¡BÂ÷¤l³q¹D¡B¤ß«ß¤£¾ã¾÷Âà±´°Q¡B¤ßŦ¹q¥Í²z¼Ò«¬¼ÒÀÀ¡C
Clinical aspect: adult cardiologist; diagnosis, treatment and prevention of arrhythmia, coronary artery disease, valvular heart disease, heart failure, and cardiomyopathy; critical medicine for acute coronary syndrome and acute decompensated heart failure; echocardiography. Research aspect: lipid science and cardiac lipotoxicity, cardiac electrophysiology, ion channels study, mechanisms of arrhythmias, computational simulation of cardiac electrophysiology.
Publication
NO | Publication |
---|---|
1 | Female showed favorable left ventricle hypertrophy regression during post-TAVR follow-up. Female showed favorable left ventricle hypertrophy regression during post-TAVR follow-up. |
2 | ¤ßŦ°IºÜ±wªÌ¥Í©R³Ì«á¤@Ó¤ë¦b«¯gºÊÅ@¨Ï¥ÎªºÁͶթMÅÜ¤Æ Trends and Changes in Intensive Care Use for Patients With Heart Failure in the Last Month of Life |
3 | Upregulated Small-Conductance Calcium-Activated Potassium Currents Contribute to Atrial Arrhythmogenesis in High-Fat Feeding Mice Upregulated Small-Conductance Calcium-Activated Potassium Currents Contribute to Atrial Arrhythmogenesis in High-Fat Feeding Mice |
4 | Spondyloarthritis and nonbacterial thrombotic endocarditis as paraneoplastic manifestations in treatment-naive Burkitt lymphoma. Spondyloarthritis and nonbacterial thrombotic endocarditis as paraneoplastic manifestations in treatment-naive Burkitt lymphoma. |
5 | ·¥§C±K«×¯×³J¥Õ¯×½è²Õ¦¨¤Î¤£¹¡©M¯×ªÕ»Ä»P¥NÁ¯gÔ¸s¤ß©Ð«¶ìªºÃöÁp Association of lipid composition and unsaturated fatty acids of VLDL with atrial remodeling in metabolic syndrome |
6 | An open-label randomized non-inferior study of generic-name and brand-name of propafenone for rhythm control in patients with paroxysmal atrial fibrillation. An open-label randomized non-inferior study of generic-name and brand-name of propafenone for rhythm control in patients with paroxysmal atrial fibrillation. |
7 | Mitochondrial Oxidative Stress Mediates Bradyarrhythmia in Leigh Syndrome Mitochondrial Disease Mice. Mitochondrial Oxidative Stress Mediates Bradyarrhythmia in Leigh Syndrome Mitochondrial Disease Mice. |
8 | Long-term High-fat Diet Consumption Depletes Glial Cells and Tyrosine Hydroxylase¡Vcontaining Neurons in the Brain of Middle-aged Rats Long-term High-fat Diet Consumption Depletes Glial Cells and Tyrosine Hydroxylase¡Vcontaining Neurons in the Brain of Middle-aged Rats |
9 | ·¥§C±K«×¯×³J¥ÕP¯f¨¤¦âªº·sÃÒ¾Ú Emerging Evidence of Pathological Roles of Very-Low-Density Lipoprotein (VLDL) |
10 | §Q¥Î¹B°Ê¤ß¹q¹Ï³q¹L²`«×¾Ç²ß¯«¸gºôµ¸§ïµ½¤ß©ÐŸ°Êªº¦´Á¶EÂ_ Exploiting exercise electrocardiography to improve early diagnosis of atrial fibrillation with deep learning neural networks. |
11 | Skin sympathetic nerve activity and ventricular arrhythmias in acute coronary syndrome Skin sympathetic nerve activity and ventricular arrhythmias in acute coronary syndrome |
12 | QTc ´Á¶¡»P¥NÁ¯gÔ¸sÓÅ骺¤ß©ÐŸ°Ê¦³Ãö QTc Interval is Associated with Atrial Fibrillation in Individuals with Metabolic Syndrome Phenotype |
13 | An artificial intelligence approach for predicting cardiotoxicity in breast cancer patients receiving anthracycline. An artificial intelligence approach for predicting cardiotoxicity in breast cancer patients receiving anthracycline. |
14 | Ãöª`·¥§C±K«×¯×³J¥Õ©ó¥NÁ©ʤßŦ¯fªºP¯f¨¤¦â¡G¯e¯f»P¾÷Âà Spotlight on very-low-density lipoprotein as a driver of cardiometabolic disorders: Implications for disease progression and mechanistic insights. |
15 | 1-ÁC»ÄÀT®ò¾J¼W±j¤º¶t¹ï¶Ý»Ì²ÓM¤j¹q¾É¶t¿E¬¡¹[³q¹D¤§±±¨î Permissive Modulation of Sphingosine-1-Phosphate-Enhanced Intracellular Calcium on BKCa Channel of Chromaffin Cells |
16 | ³±¹q©Ê·¥§C±K«×¯×³J¥Õ»¤µo¤p¹«¸£³¡µoª¢©M»{ª¾¥\¯à»Ùê Electronegative very-low-density lipoprotein induces brain inflammation and cognitive dysfunction in mice |
17 | ¦b¬Ì±¡¤j¬y¦æ®É°õ¦æ«aª¬°Ê¯ß¤¶¤JªvÀø¡H¤ß¾ÉºÞ«Ç¦]À³ªZº~ªÍª¢¤§¥i¦æ¼Ò¦¡ Performing a percutaneous coronary intervention in the Pandemic?A paradigm for a Catheterization Laboratory responding to Covid-19 |
18 | High Skin Sympathetic Nerve Activity in Patients with Recurrent Syncope High Skin Sympathetic Nerve Activity in Patients with Recurrent Syncope |
19 | ·¥§C±K«×¯×³J¥Õ¦b¥NÁ¯gÔ¸sªº¤ß©Ð¯fÅܪºP¯f¨¤¦â The Pathogenic Role of Very Low Density Lipoprotein on Atrial Remodeling in the Metabolic Syndrome |
20 | Role of low-density lipoprotein in early vascular aging associated with systemic lupus erythematosus Role of low-density lipoprotein in early vascular aging associated with systemic lupus erythematosus |
21 | ¯×½è©M¯×³J¥Õ¹ï¥Î©ó¤ßŦ²Õ´¦A¥Íªº¶¡½è·F²ÓMªº¼vÅT Effects of Lipids and Lipoproteins on Mesenchymal Stem Cells Used in Cardiac Tissue Regeneration |
22 | À\«á·¥§C±K«×¯×³J¥Õ¦b¥NÁ¯gÔ¸s¤§¤ß©Ð«ºcµo®i¤¤ªº§@¥Î The role of postprandial very-low-density lipoprotein in the development of atrial remodeling in metabolic syndrome |
23 | ¦b¬Ì±¡¤j¬y¦æ®É°õ¦æ«aª¬°Ê¯ß¤¶¤JªvÀø¡H ¤ß¾ÉºÞ«Ç¦]À³·s«aªÍª¢¤§¥i¦æ¼Ò¦¡ Performing a Percutaneous Coronary Intervention in the Pandemic? A Paradigm for a Catheterization Laboratory Responding to Covid-19 |
24 | ¶u¡Ð¸²µå¿}¦@¦PÂà¹B³J¥Õ2§í¨î¾¯ empagliflozin ´î½w°ª¦åÀ£¤ß°IºÜ¤j¹«ªº¤ßŦÅÖºû¤Æ»P§ïµ½¦å«¬°Ê¤O¾Ç The Sodium-Glucose Co-transporter 2 Inhibitor Empagliflozin Attenuates Cardiac Fibrosis and Improves Ventricular Hemodynamics in Hypertensive Heart Failure Rats |
25 | ¦P¨B¤ß¹q¹Ï»P«I¤J©Ê°Ê¯ß¦åÀ£¬ö¿ý Simultaneous Electrocardiography Recording and Invasive Blood Pressure Measurement in Rats |
26 | adipoectin T94G ¦h«¬©Ê»P¦~»´«¬¹x©T©Ê°ª¦åÀ£¯f¤H¬ÛÃö©Ê¤§±´°Q Association between adiponectin T94G polymorphism and resistant T hypertension in young-onset Taiwanese patients |
27 | ·¥§C±K«×¯×³J¥Õ½Õ¸`¶tÂ÷¤l·P´ú³J¥ÕSTIM1§í¨îSOCE³y¦¨¤ß©Ð¤ß¦Ù¦Ù³J¥Õ¥¢§Ç Very Low-Density Lipoproteins of Metabolic Syndrome Modulates STIM1, Suppresses Store-Operated Calcium Entry, and Deranges Myofilament Proteins in Atrial Myocytes |
28 | Immunoregulatory effects of very low density lipoprotein from healthy individuals and metabolic syndrome patients on glial cells Immunoregulatory effects of very low density lipoprotein from healthy individuals and metabolic syndrome patients on glial cells |
29 | ¶ÀáIËïl¥ÍKMUP-1¤ÏÂà°ª¿}¬r©Ê¬¡¤Æ¤§Kv³q¹D¸g¥ÑcAMP/PKA°T®§¸ô®|©ó¤j¹«¯Ø®q¤A«¬²ÓM Xanthine-derived KMUP-1 reverses glucotoxicity-activated Kv channels through the cAMP/PKA signaling pathway in rat pancreatic £] cells |
30 | °ª¯×¶¼¹´c¤Æ¦~ªø°ª¦åÀ£¹«¤§¥ª¤ß©Ð»P¤ß«Ç«¶ì High fat diet aggravates atrial and ventricular remodeling of hypertensive heart disease in aging rats |
31 | Association between modified CHA2DS2-VASc Score with Ankle-Brachial index < 0.9. Association between modified CHA2DS2-VASc Score with Ankle-Brachial index < 0.9. |
32 | Range of L5 LDL levels in healthy adults and L5¡¦s predictive power in patients with hyperlipidemia or coronary artery disease Range of L5 LDL levels in healthy adults and L5¡¦s predictive power in patients with hyperlipidemia or coronary artery disease |
33 | V141M KCNQ1°ò¦]¬ðÅܳy¦¨µu¢ß¢â¯gÔ¸s¤§¾÷Âà±´°Q- ¹q¸£¼Ò«¬¼ÒÀÀ¬ã¨s Pro-arrhythmogenic effects of the V141M KCNQ1 mutation in short QT syndrome and its potential therapeutic targets - insights from modeling |
34 | ¥NÁ¯gÔ¸s¤§·¥§C±K«×¯×³J¥Õ½Õ¸`¶¡»Ø³s±µ»P©µ½w¤ßŦ¤º¹q¶Ç¾É Very-low-density lipoprotein of metabolic syndrome modulates gap junctions and slows cardiac conduction |
35 | ³±¹q©Ê§C±K«×¯×³J¥Õ»¤µo¥NÁ¯gÔ¸s¯×ªÕ²Õ´µoª¢¤ÏÀ³ Electronegative Low-density Lipoprotein L5 Induces Adipose Tissue Inflammation Associated with Metabolic Syndrome |
36 | ªÅ®ð¦Ã¬VPM»P°Ê¯ßµw¤Æ Air Pollution Particular Matter and Atherosclerosis |
37 | ¥k¤ß©Ð¹[Â÷¤l³q¹DKCNQ1°ò¦]¦b³N«á¤ß©ÐŸ°Êªº½Õ±± Modulation of Potassium Channel KCNQ1 Transcript in Right Atrial Appendage of Patients with Postoperative Atrial Fibrillation |
38 | ¥NÁ¯gÔ¸s¤¤ªº«D±`§C±K«×¯×³J¥Õ³y¦¨¤ß©Ð¯×½è¨I¿n»P¤ß©ÐŸ°Ê ªºµo¥Í¦³Ãö VLDL from metabolic syndrome individuals enhanced lipid accumulation in atria with association of susceptibility to atrial fibrillation |
39 | Areca Nut Chewing Complicated with Non-Obstructive and Obstructive ST Elevation Myocardial Infarction Areca Nut Chewing Complicated with Non-Obstructive and Obstructive ST Elevation Myocardial Infarction |
40 | ¬ü°ê2013¦~·sª©Áx©T¾JªvÀø«ü¤Þ¤¤ªº¥|¤j¥L¥ÅÃþ°Áx©T¾JÃĪ«¨ü´fªÌ¦å¼ß¤¤¦³¸û°ª¿@«×ªº³±¹q©Ê§C±K«×¯×³J¥ÕÁx©T¾J Four Statin Benefit Groups Defined by The 2013 ACC/AHA New Cholesterol Guideline are Characterized by Increased Plasma Level of Electronegative LDL |
41 | µn²¼ö¨Öµo²rÃz©Ê¤ß¦Ùª¢»P¥ð§J¸g¥D°Ê¯ß®ð²yÀ°®ú¤ä«ù Fulminant dengue myocarditis complicated with profound shock and fatal outcome under intra-aortic balloon pumping support |
42 | «aª¬°Ê¯ß°¼ªK´`Àô¦b¦³ÅãµÛ«aª¬°Ê¯ß¯e¯f¤§¦åºÞÂX±i¯g±wªÌ¨¤W Coronary Collateral Circulation in Patients of Coronary Ectasia with Significant Coronary Artery Disease |
43 | KCNQ1¿ï¾Ü©Ê°Å±µªº§ïÅܽո`¤ßŦIKs¹q¬y»P°Ê§@¹q¦ì¦b·¥¤Æ Modulation of KCNQ1 Alternative Splicing Regulates Cardiac IKs and Action Potential Repolarization |
44 | µu®É¶¡§ë¤©N-acetylcysteine, probucol, ascorbic acid¦bÅã¼v¾¯²ÓM¬r©Êªº¼vÅT Impact of short-duration administration of n-acetylcysteine, probucol and ascorbic acid on contrast-induced cytotoxicity. |
45 | Â÷¤l©Ê·Ó¼v¾¯¤ñ«DÂ÷¤l©Ê·Ó¼v¾¯¦b¿}§¿¯fµÇŦ¤Þ°_§ó©úÅ㪺ä¤` Ionic contrast media induced more apoptosis in diabetic kidney than nonionic contrast media. |
46 | JNK/ATF2³~®|»PÅã¼v¾¯³y¦¨¤§²ÓMä¤`¦³Ãö JNK/ATF2 Pathway Is Involved in Iodinated Contrast Media-Induced Apoptosis |
47 | «æ©Ê¤@®ñ¤ÆºÒ¤¤¬r³y¦¨ST ¬q¤W¤É¤§¤ß¦Ù±ð¶ë ¡X¨u¨£ªº¯f¾ú³ø§i Acute carbon monoxide poisoning resulting in ST elevation myocardial infarction: a rare case report. |
48 | Mismatch between arterial stiffness increase and left ventricular diastolic dysfunction Mismatch between arterial stiffness increase and left ventricular diastolic dysfunction |
49 | ¥HµÎ±i¤¤´Á¤G¦yäÀôªº¹B°Ê«¬ºA¨Ó¤À¿ë¥ª¤ß«ÇªºµÎ±i¥\¯à Differentiation of left ventricular diastolic function by mid-diastolic mitral annular motion patterns. |
50 | ·P¬V©Ê¤ß¤º½¤ª¢»P¸²µå½¤ª¢-¯f¾ú³ø§i Infective endocarditis with uveitis |
51 | §Ü®ñ¤Æ¾¯Acetylcysteine ¤Îprobucol¹ïSTZ»¤µo¿}§¿¯f¹«¤º¥Í©ÊµÇglutathione peroxidaseªº§@¥Î Effects of acetylcysteine and probucol on contrast medium-induced depression of intrinsic renal glutathione peroxidase activity in diabetic rats |
52 | ·P¬V©Ê¤ß¤º½¤ª¢»P¸²µå½¤ª¢--¯f¾ú³ø§i Infective endocarditis with uveitis: a rare case report |
53 | Åã¼v¾¯¹ï¤ß¦Ù±ÛÂà³J¥ÕI§K¬Ì¤ÀªR´ú©wªº°°¶§©Ê¤zÂZ Positive interference from contrast media in cardiac troponin I immunoassays |
54 | ¤£¦PªºÅã¼v¾¯¹ï¥¿±`¹«©M¿}§¿¯f¹«¤ßŦ©MµÇŦ§Ü®ñ¤Æ»Ã¯À¬¡©Êªº¼vÅT Effects of different contrast media on glutathione peroxidase and superoxide dismutase activities in the heart and kidneys of normal and streptozotocin-induced diabetic rats. |
55 | °ªº¯³zÀ£Â÷¤lÅã¼v¾¯¹ïStreptozotocin »¤µoªº¿}§¿¯f¹«µÇ§Ü®ñ¤Æ¬¡©Êªº«æ©Ê§@¥Î Acute effect of ionic high osmolar contrast medium on renal antioxidant enzyme activity in streptozotocin-induced diabetic rats |
56 | Terlipressin ¤Þ°_¤§«æ©Ê¤ß¦Ù±ð¶ë- ¤@¯f¨Ò³ø§i¤Î¤åÄm¦^ÅU Terlipressin-related acute myocardial infarction: a case report and literature review |
Project
NO |
YEAR ¡X Source ¡X No ¡X Type
Project Name
|
Duration |
---|---|---|
1 |
113 ¡X KT °ªÂå²M¤j ¡X KT113P012 ¡X 1 Ó¤H«¬
¶}µo¹w´ú·s«¬¤fªA§Ü¾®¦å¾¯¤§ÃĮĻP¥X¦å°Æ§@¥Î¤§°ò¦]¼Ð°OÀË´ú¥¥x(Development a diagnosis platform for predicting the efficacy and bleeding adverse events of direct oral anticoagulants (DOACs))
|
2024/01/01 ~ 2024/12/31 |
2 |
113 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSTC113-2314-B-037-055 ¡X 1 Ó¤H«¬
·¥§C±K«×¯×³J¥Õ±µ¨ü¾¹©M¯×³J¥Õ¯×ªÕ?ªº¬Û¤¬§@¥Î¹ï¤ß©Ð¦Ù¯f¤§¼vÅT( )
|
2024/08/01 ~ 2025/07/31 |
3 |
112 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSTC112-2314-B-037-069 ¡X 1 Ó¤H«¬
·¥§C±K«×¯×³J¥Õ±µ¨ü¾¹ªº¿ï¾Ü©Ê°Å±µÅܲ§«¬©ó½Õ±±¤ßŦ¯×½è§Q¥Î¤§¨¤¦â( )
|
2023/08/01 ~ 2024/07/31 |
4 |
112 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X NSTC113-2813-C-037-028-B ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
113¦~«×¤j±M¾Ç¥Í¬ã¨spµe-±i¤¯Ãh(ÃľÇ3)( )
|
2024/07/01 ~ 2025/02/28 |
5 |
112 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X NSTC113-2813-C-037-030-B ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
113¦~«×¤j±M¾Ç¥Í¬ã¨spµe-ªô«Fºû(Âå¾Ç4)( )
|
2024/07/01 ~ 2025/02/28 |
6 |
111 ¡X KK °ª¬ì¤j°ªÂå²£¾Ç¦X§@¸É§U ¡X ¡X
ºô²y¿ï¤âªº¤H¤u´¼¼z¤ßŦµû¦ô¨t²Î( )
|
2022/11/01 ~ 2023/10/31 |
7 |
111 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST109-2314-B-037-111-MY3 ¡X 1 Ó¤H«¬
·¥§C±K«×¯×³J¥Õ/±µ¨ü¾¹°T®§½Õ±±¤ßŦ¦Û«ß¯«¸g¤ä°t¹ï¤ß«ß¤£¾ãµo¥Íªº¼vÅT(3/3)( )
|
2022/08/01 ~ 2023/07/31 |
8 |
111 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X NSTC112-2813-C-037-060-B ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
112¦~«×¤j±M¾Ç¥Í¬ã¨spµe-¶À¥[¨Î(Âå¾Ç2)( )
|
2023/07/01 ~ 2024/02/29 |
9 |
111 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X NSTC112-2813-C-037-061-B ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
112¦~«×¤j±M¾Ç¥Í¬ã¨spµe-©P«G©y(Âå¾Ç3)( )
|
2023/07/01 ~ 2024/02/29 |
10 |
110 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST109-2314-B-037-111-MY3 ¡X 1 Ó¤H«¬
·¥§C±K«×¯×³J¥Õ/±µ¨ü¾¹°T®§½Õ±±¤ßŦ¦Û«ß¯«¸g¤ä°t¹ï¤ß«ß¤£¾ãµo¥Íªº¼vÅT(2/3)( )
|
2021/08/01 ~ 2023/07/31 |
11 |
110 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X MOST111-2813-C-037-080-B ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
111¦~«×¤j±M¾Ç¥Í¬ã¨spµe-³¯º~©y(Âå¾Ç3)( )
|
2022/07/01 ~ 2023/02/28 |
12 |
109 ¡X I °ê½Ã°| ¡X NHRI-EX110-10724SC ¡X
¯×³J¥Õ¦å¯×©ó¦´Á¤ß©Ð¤ß¦Ù¯fÅÜ»P¤ß©ÐŸ°Êµo¥ÍªºÂàĶÂå¾Ç¬ã¨s( )
|
2021/01/01 ~ 2021/12/31 |
13 |
109 ¡X KP °ªÂå«Ì¬ì¤j ¡X NPUST-KMU-109-P005 ¡X 1 Ó¤H«¬
¯×½è¬r©Ê¾ÉP¤ß©Ð¤ß¦Ù¯fÅܤ§½Þ¼Ò¦¡ÂàĶ¬ã¨s( )
|
2020/01/01 ~ 2020/12/31 |
14 |
109 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST109-2314-B-037-111-MY3 ¡X 1 Ó¤H«¬
·¥§C±K«×¯×³J¥Õ/±µ¨ü¾¹°T®§½Õ±±¤ßŦ¦Û«ß¯«¸g¤ä°t¹ï¤ß«ß¤£¾ãµo¥Íªº¼vÅT(1/3)( )
|
2020/08/01 ~ 2023/07/31 |
15 |
109 ¡X X °ª©_¦X§@pµe ¡X 110CM-KMU-01 ¡X
³z¹L°ò¦]¦h«¬©Ê±´°Q§ÜÀùÃĪ«¹ï©ó¤k©Ê¨ÅÀù±wªÌ©Ò³y¦¨¤ßŦ¬r©Ê¤§ºë·ÇÂå¾Ç¬ã¨s( )
|
2021/08/01 ~ 2022/07/31 |
16 |
109 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X MOST110-2813-C-037-165-B ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
110¦~«×¤j±M¾Ç¥Í¬ã¨spµe-¤~ªé§D(Âå¾Ç3)( )
|
2021/07/01 ~ 2022/02/28 |
17 |
108 ¡X I °ê½Ã°| ¡X NHRI-EX109-10724SC ¡X
¯×³J¥Õ¦å¯×©ó¦´Á¤ß©Ð¤ß¦Ù¯fÅÜ»P¤ß©ÐŸ°Êµo¥ÍªºÂàĶÂå¾Ç¬ã¨s( )
|
2020/01/01 ~ 2020/12/31 |
18 |
108 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST108-2314-B-037-098 ¡X 1 Ó¤H«¬
·¥§C±K«×¯×³J¥Õ¬ÛÃö¤À¤l°T¸¹©ó¤ß©Ð¯fÅܤ¤¤§P¯f¨¤¦â( )
|
2019/08/01 ~ 2020/07/31 |
19 |
108 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X MOST109-2813-C-037-044-B ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
109¦~«×¤j±M¾Ç¥Í¬ã¨spµe-¶À¤é·¢(Âå¾Ç5)( )
|
2020/07/01 ~ 2021/02/28 |
20 |
107 ¡X I °ê½Ã°| ¡X NHRI-EX108-10724SC ¡X
¯×³J¥Õ¦å¯×©ó¦´Á¤ß©Ð¤ß¦Ù¯fÅÜ»P¤ß©ÐŸ°Êµo¥ÍªºÂàĶÂå¾Ç¬ã¨s(The Alliance of Lipoproteins-Lipids with Early Atrial Myopathy and Atrial Fibrillation)
|
2019/01/01 ~ 2019/12/31 |
21 |
107 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST107-2314-B-037-110 ¡X 1 Ó¤H«¬
·¥§C±K«×¯×³J¥Õ¦b¤ß©Ð¯fÅܤ¤ªº¥NÁ²§±`¤§P¯f¨¤¦â( )
|
2018/08/01 ~ 2019/07/31 |
22 |
107 ¡X X °ª©_¦X§@pµe ¡X 108CM-KMU-09 ¡X
±´°Q·¥§C±K«×¯×³J¥Õ±µ¨üÅé©ó¥NÁ¯gÔ¸s±wªÌ¤ßŦ«¶ì¤§¨¤¦â( )
|
2019/05/01 ~ 2020/04/30 |
23 |
106 ¡X I °ê½Ã°| ¡X NHRI-EX107-10724SC ¡X
¯×³J¥Õ¦å¯×©ó¦´Á¤ß©Ð¤ß¦Ù¯fÅÜ»P¤ß©ÐŸ°Êµo¥ÍªºÂàĶÂå¾Ç¬ã¨s( )
|
2018/01/01 ~ 2018/12/31 |
24 |
106 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST104-2314-B-037-080-MY3 ¡X 1 Ó¤H«¬
·¥§C±K«×¯×³J¥Õ¦b¥NÁ¯gÔ¸s¤¤µo®i¤ß©ÐŸ°Ê§êºtªº¨¤¦â(3/3)( )
|
2017/08/01 ~ 2018/07/31 |
25 |
105 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST104-2314-B-037-080-MY3 ¡X 1 Ó¤H«¬
·¥§C±K«×¯×³J¥Õ¦b¥NÁ¯gÔ¸s¤¤µo®i¤ß©ÐŸ°Ê§êºtªº¨¤¦â(2/3)( )
|
2016/08/01 ~ 2018/07/31 |
26 |
105 ¡X TP ³»¦ypµe(°ªÂå) ¡X KMU-TP105D08 ¡X
¤lpµe¤K¡B·¥§C±K«×¯×³J¥Õ¤zÂZ¤ß©Ð¦Ù²ÓM²É½uÅé¥\¯à-¥NÁ¯gÔ¸s¼vÅT¤ß©ÐŸ°Êµo¥Íªº¥i¯à¾÷Âà( )
|
2016/11/01 ~ 2017/10/31 |
27 |
104 ¡X NK °ªÂå-¤¤¤s¦X§@pµe ¡X NSYSUKMU104-P027 ¡X 1 Ó¤H«¬
¤ßŦ¹q¥Í²z¼Ò«¬¼ÒÀÀ¥¥x( )
|
2015/01/01 ~ 2015/12/31 |
28 |
104 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST104-2314-B-037-080-MY3 ¡X 1 Ó¤H«¬
·¥§C±K«×¯×³J¥Õ¦b¥NÁ¯gÔ¸s¤¤µo®i¤ß©ÐŸ°Ê§êºtªº¨¤¦â(1/3)( )
|
2015/08/01 ~ 2018/07/31 |
29 |
104 ¡X TP ³»¦ypµe(°ªÂå) ¡X KMU-TP104D10 ¡X
¤lpµe¤Q¡B¥NÁ¯gÔ¸s¤¤«D±`§C±K«×¯×³J¥Õ¹ï¤ß©Ð¶¡»Ø³s±µªº½Õ±±( )
|
2015/10/01 ~ 2016/09/30 |
30 |
103 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST103-2314-B-037-053 ¡X 1 Ó¤H«¬
¿ï¾Ü©Ê°Å±µ¬°³y¦¨¤ß©ÐŸ°Êªº¹q®ð«ºc¤§·sP¯f¾÷Âà( )
|
2014/08/01 ~ 2015/07/31 |
31 |
103 ¡X TP ³»¦ypµe(°ªÂå) ¡X KMU-TP103D05 ¡X
·L¤p®ÖÁޮֻĦb¥NÁ¯gÔ¸s¦X¨Ö¯×ªÕ¨xµo¥Í¤ß©ÐŸ°ÊªºÃöÁ䨤¦â( )
|
2014/08/01 ~ 2015/07/31 |
32 |
102 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSC102-2314-B-037-041 ¡X 1 Ó¤H«¬
¸ÑªR°ò¦]¿ï¾Ü©Ê°Å±µ»P¤ß«ß¤£¾ãªºÃö«Y( )
|
2013/08/01 ~ 2014/07/31 |
33 |
099 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSC99-2221-E-037-001 ¡X 1 Ó¤H«¬
¹B¥Î°ò¦]Âà´Þ»P¹q®ð¥Í²z§Þ³N±´°Q¿ï¾Ü©Ê°Å±µ¦b¹[Â÷¤l³q¹DKCNQ1¤§½Õ±±¾÷¨î( )
|
2010/08/01 ~ 2011/07/31 |
34 |
097 ¡X M °ªÂå(ºØ¤lpµe) ¡X KMU-M098027 ¡X
¿}§¿¯f¤ß¦Ù¯fÅܤ§¹w«á¬ÛÃö¦]¤l¤Î°ò¦]¦h§ÎÅܤÆ( )
|
2009/01/01 ~ 2009/12/31 |